Agilent agrees to buy pathology AI company Proscia for up to $270 million

What Agilent announced

On 13 October 2026 Agilent Technologies said it had signed a definitive agreement to buy Proscia, a Philadelphia company that makes software for digital pathology, the practice of scanning glass tissue slides and reading them on screen instead of under a microscope. Agilent will pay $240 million in cash at closing and up to $30 million more if unspecified performance milestones are met. Proscia published the same release on its own site.

Proscia’s main product is Concentriq, a platform that stores whole-slide images and connects slide scanners, laboratory information systems, image-analysis tools and AI models. According to the release, Proscia serves more than 4,000 laboratories, hospitals and clinics and 16 of the top 20 pharmaceutical companies, and its revenue over the last twelve months was more than $18 million. It was named 2026 Best in KLAS for digital pathology, a ranking based on customer surveys by the research firm KLAS.

The deal still has to clear customary closing conditions. Agilent expects it to close early in its fiscal year 2027, which starts on 1 November 2026, without naming a month. On closing, Proscia will become part of Agilent’s Life Sciences and Diagnostics Markets Group. Reuters described the purchase as part of the laboratory equipment maker’s push into AI-enabled diagnostics.

Why a lab-equipment company wants pathology software

Agilent is best known for analytical instruments, reagents and laboratory services, and reported $6.95 billion in revenue in fiscal 2025. In pathology it already sells staining instruments and reagents, the chemistry that makes cells and proteins visible on a slide. The Proscia purchase adds the layer that sits after the scanner: where images are stored, how pathologists review them, and where AI models run on them.

It follows two other pathology moves by Agilent this year. In June it completed its $950 million acquisition of Biocare Medical, a maker of immunohistochemistry and molecular pathology stains and instruments. In September it launched the Agilent S540MD slide scanner in the United States, a 540-slide whole-slide scanner that Agilent says is a rebranded Hamamatsu NanoZoomer S540MD. Add Proscia, and Agilent would sell the stain, the scanner and the software that pathologists read cases in.

The two companies are not strangers. They signed a multi-year distribution agreement in September 2022 to sell a combined digital pathology system, which the release says the acquisition builds on. Agilent chief executive Padraig McDonnell said the deal “establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation.”

Where the AI comes in

Proscia now calls itself “the pathology AI company.” In October 2024 it launched Concentriq Embeddings, a feature that turns whole-slide images into numerical representations using open pathology and vision foundation models such as DINOv2, PLIP, ConvNext and CTransPath, so data-science teams can build classifiers and biomarker models without moving their image archives elsewhere.

In June 2026 the company released what it called the Fifth Generation of Concentriq, which it describes as its biggest platform change in five years. Proscia says it brings “domain-specific frontier vision, language, and multimodal models” into the platform to help with tasks around case review, such as navigating tissue and lymph node counts, and to speed up biomarker work for drug developers. The company says the system serves laboratories that handle 12 million patient cases a year.

A third product points at why drug companies care. Proscia Aperture, announced in September 2025, uses AI to scan routine pathology images alongside molecular and clinical records to flag patients who might qualify for clinical trials or targeted therapies at the moment of diagnosis. Agilent’s release ties this to its companion diagnostics business, the tests drug makers use to decide which patients get a given therapy, and to a “growing repository of real-world data.”

Healthcare AI is moving from demos into regulated workflows in several places at once. Britain has opened a third phase of its AI Airlock regulatory sandbox, and clinical studies such as the Lancet feasibility study of Google’s AMIE are testing AI tools with real patients. Proscia is an example of the less visible layer: the data infrastructure hospitals and pharma companies need before any model can be used on their slides.

What the FDA has cleared

Concentriq AP-Dx, the diagnostic version of the platform, received FDA 510(k) clearance for primary diagnosis in February 2024, paired with a Hamamatsu NanoZoomer S360MD scanner. Proscia said its multi-site study found digital reads non-inferior to glass-slide reads. A second clearance, K261380, was received by the FDA on 27 April 2026 and decided on 5 August 2026. It added the Leica Aperio GT 450 DX scanner, cloud deployment and a predetermined change control plan, which Proscia says lets it validate more FDA-cleared scanners, image formats and displays without filing a new 510(k) each time.

One detail matters for this deal. The 510(k) summary lists the addition of the NanoZoomer S540MD, the same scanner Agilent now sells under its own name, among the purposes of the submission, but the cleared table of interoperable components names only the Leica Aperio GT 450 DX and the Hamamatsu S360MD. APO | APE News was first to point this out. The change control plan may offer a route to add it later, but as of the clearance the Agilent-branded scanner is not on Concentriq AP-Dx’s cleared list for primary diagnosis.

The price and who gets paid

Neither company disclosed Proscia’s growth rate or profitability. On the one revenue number given, the $240 million upfront is at most about 13 times trailing revenue, and up to about 15 times including the milestones, by our arithmetic; because Agilent gave revenue as a floor, the real multiple is somewhat lower. Proscia said in its March 2025 funding announcement that a $50 million round led by Insight Partners brought its total raised to $130 million.

Agilent’s legal adviser is DLA Piper and Proscia’s is Cooley. The release names no financial adviser for either side and does not say what the $30 million in milestones depends on. Agilent says Proscia’s recurring software revenue will add a “high-growth, high-margin” business to its pathology portfolio, but has not said how much it expects the deal to add to sales or earnings.

What it means for labs and drug companies

Proscia’s pitch to laboratories has been neutrality. Its platform works with scanners from several manufacturers and AI applications from many developers, and Agilent’s own release calls it “vendor-agnostic.” Proscia’s August announcement said labs need “flexibility to adopt additional technologies unconstrained by the limits of proprietary ecosystems.” After the deal, that neutral software layer will belong to a company that also sells scanners and stains.

Proscia chief executive David West said Agilent shares a vision for “open, digital, and AI-enabled solutions” and that the companies would keep “the flexibility they need across clinical and life-sciences workflows.” Labs using Leica or other scanners with Concentriq will be watching whether that holds in pricing, support and the order in which new integrations arrive.

For pharma customers, the combined offer is a pipeline from tissue staining to AI-derived biomarkers to companion diagnostics under one supplier. That could make large trials easier to run, and it also concentrates sensitive patient-derived image data with one more large vendor. Meta’s recent health studies built on five million patient records show how much value AI developers see in such datasets.

Limitations and what to watch

This is an agreement, not a completed sale. Customary conditions, which can include antitrust review, still apply, and the companies have not given a target month beyond early fiscal 2027. All of the customer counts, rankings and AI capabilities in this article come from Agilent and Proscia; we did not test Concentriq, and the vendors have not published independent evaluations of the Fifth Generation AI features.

Things worth watching: the closing date; whether Proscia adds the Agilent S540MD to Concentriq AP-Dx through its change control plan or a new filing; whether Concentriq keeps supporting rival scanners on equal terms; what the $30 million milestones turn out to be; and whether Agilent reports Proscia’s contribution separately in its fiscal 2027 results.